Literature DB >> 6650595

Pharmacodynamics of ritodrine in pregnant women during preterm labor.

S N Caritis, L S Lin, G Toig, L K Wong.   

Abstract

We evaluated the relationship of ritodrine concentration to several maternal variables and to fetal heart rate in 17 women who received the drug for inhibition of preterm labor. Ritodrine was measured by high-performance liquid chromatography with electrochemical detection. Ritodrine increased maternal and fetal heart rate and decreased serum potassium in a dose-related manner, but wide variability was noted between patients and within individual patients. Tachyphylaxis of the maternal heart rate response to continuing treatment with ritodrine was seen in at least seven women. Maternal blood pressure, serum glucose concentration, and frequency of uterine contractions were changed by ritodrine treatment, but the changes in these variables were not closely correlated to the concentration of ritodrine (r less than or equal to 0.30 in all cases). The maximal infusion rate and the concentration of ritodrine in maternal serum after 4 hours of treatment were significantly (p less than 0.001) correlated with the frequency of uterine contractions prior to treatment. Successful inhibition of labor was achieved with serum concentrations of 15 to 31 ng/ml in 10 of 17 women; in six of the other seven women, labor could not be inhibited in spite of serum concentrations of 90 to 146 ng/ml. Side effects, such as hypotension, vomiting, chest discomfort, and shortness of breath, were most commonly observed when the infusion rate and concentration of ritodrine were increasing.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6650595     DOI: 10.1016/0002-9378(83)90030-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  Epidural anesthesia for cesarean section in triplet pregnant women with toxemia and complications of ritodrine therapy: Five case reports.

Authors:  Y Yamamori; Y Kawano; Y Nakamura; A Tanaka; Y Kosaka
Journal:  J Anesth       Date:  1995-03       Impact factor: 2.078

Review 2.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

3.  Ritodrine sulphation in the human liver and duodenal mucosa: interindividual variability.

Authors:  G M Pacifici; M C Quilici; B Giulianetti; R Spisni; M Nervi; L Giuliani; R Gomeni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

4.  Pharmacokinetics of ritodrine diastereomers in patients pregnant with singletons and twins.

Authors:  A Konda; T Ito; H Yoshida; T Toda; T Hayakawa; N Inotsume
Journal:  Eur J Clin Pharmacol       Date:  2009-05-27       Impact factor: 2.953

5.  Ritodrine pharmacokinetics in twin pregnancy patients.

Authors:  A Konda; A Nodai; M Soma; Y Koga; H Yoshida; T Toda; T Hayakawa; N Inotsume
Journal:  Eur J Clin Pharmacol       Date:  2007-12-18       Impact factor: 2.953

Review 6.  Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects.

Authors:  B Ostádal; V Pelouch; I Ostádalová; O Nováková
Journal:  Mol Cell Biochem       Date:  1995 Jun 7-21       Impact factor: 3.396

Review 7.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.